News Release Details

(Oxfordshire, UK and Pennsylvania and Maryland, US, 16 July 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announce the publication of “Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma” in a special issue on uveal melanoma in Cancers, an international, peer-reviewed monthly journal.  Written by Dr. Bertil Damato, Dr. Richard Carvajal and experts at Immunocore, the paper provides an overview of the biology of uveal melanoma, the use of immunotherapy to treat metastatic disease and reviews tebentafusp, an investigational agent being studied for the treatment of metastatic uveal melanoma.

Review Highlights¹
•    Uveal melanoma is a rare and aggressive form of eye cancer that typically has a poor prognosis once it spreads beyond the eye.2 Nearly half of all patients diagnosed with uveal melanoma go on to develop metastatic disease. The median survival time after detection of metastases is around one year.2 Uveal melanomas have several characteristics that make them difficult to treat, including a low tumour mutational burden and low PD-L1 expression.¹
•    Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. It is the first molecule developed using Immunocore’s ImmTAC^® technology platform designed to redirect T cells to recognise and kill cancer cells. 
•    Several studies with tebentafusp in both metastatic uveal melanoma and metastatic cutaneous melanoma are ongoing.

“With limited treatment options, the life expectancy of patients with metastatic uveal melanoma is dismal so that more effective therapies are urgently needed,” said Dr. Damato, Senior Clinical Research Fellow at the University of Oxford. “We are encouraged by the work Immunocore is doing in the area of uveal melanoma.”

Please follow this link to read the full Review: https://www.mdpi.com/2072-6694/11/7/971

Please click on the link below to download the full Press Release: